文章摘要
袁 芳,苑朋彬,郑彦宁.新冠疫情下生物医药行业发展机遇研究[J].全球科技经济瞭望,2022,37(11):28~33
新冠疫情下生物医药行业发展机遇研究
Research on the Development Opportunities for the BiomedicalIndustry Under the COVID-19 Epidemic
投稿时间:2022-08-29  
DOI:10.3772/j.issn.1009-8623.2022.11.005
中文关键词: 新冠疫情;生物医药;mRNA 技术;人工智能辅助药物研发
英文关键词: COVID-19 epidemic; biomedical industry; mRNA technology; artificial intelligence-assisted drugresearch
基金项目:项目来源:中国科学技术信息研究所创新研究基金青年项目“后疫情时代生物医药产业的发展变化及机遇研究”(QN2021-04)。
作者单位
袁 芳  
苑朋彬  
郑彦宁  
摘要点击次数: 966
全文下载次数: 0
中文摘要:
      2020 年初,新型冠状病毒在全球开始大流行。众多行业以及人们的生活都在不同程度地受到新冠疫情的影响。生物医药行业是与新冠疫情联系最为密切的行业。各国政府也在加大生物医药相关产业的资助力度,检测试剂、疫苗、抗病毒药物等的研发热度与市场需求显著增加。此外,新冠疫情下,各国对生物医药行业的政策规划更偏向智能化、数字化。同时,生物安全防御战略得到了各国政府的高度重视。后疫情时代,生物医药行业的信使核糖核酸(mRNA)技术、人工智能辅助药物研发等领域将迎来巨大的发展机遇。
英文摘要:
      In early 2020, the COVID-19 epidemic began globally. All industries and people’s lives are affected to various degrees by COVID-19. The biomedical industry, as the industry most closely related to the COVID-19 epidemic, has also continuously received increased funding from governments. The research enthusiasm and market demand for such testing reagents, vaccines, and antiviral drugs have increased significantly. In addition, the policy planning for the biomedical industry has shown a trend of intelligent and digital development under the COVID-19 epidemic. At the same time, the biosecurity defense strategy has been highly valued by the governments. In the post-epidemic era, the fields of mRNA technology and artificial intelligence-assisted drug research will usher in huge development opportunities.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮